These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10810635)

  • 21. Ribozymes. Evolution ex vivo.
    Szostak JW
    Nature; 1993 Jan; 361(6408):119-20. PubMed ID: 7678448
    [No Abstract]   [Full Text] [Related]  

  • 22. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.
    Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW
    Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro selection of hairpin ribozymes.
    Sargueil B; Burke JM
    Methods Mol Biol; 1997; 74():289-300. PubMed ID: 9204444
    [No Abstract]   [Full Text] [Related]  

  • 24. Application of ribozymes to cancer gene therapy.
    Kashani-Sabet M; Scanlon KJ
    Cancer Gene Ther; 1995 Sep; 2(3):213-23. PubMed ID: 8528965
    [No Abstract]   [Full Text] [Related]  

  • 25. [Ribozymes--against virus diseases and cancer].
    Thrane PS; Lyngstadaas SP
    Tidsskr Nor Laegeforen; 1996 May; 116(12):1445-6. PubMed ID: 8650628
    [No Abstract]   [Full Text] [Related]  

  • 26. Ribozyme gene therapy for cancer nears clinical trials.
    Oncology (Williston Park); 1995 Nov; 9(11):1180, 1182. PubMed ID: 8703687
    [No Abstract]   [Full Text] [Related]  

  • 27. Ribozymes: Flexible molecular devices at work.
    Talini G; Branciamore S; Gallori E
    Biochimie; 2011 Nov; 93(11):1998-2005. PubMed ID: 21740954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlled, targeted, intracellular expression of ribozymes: progress and problems.
    Rossi JJ
    Trends Biotechnol; 1995 Aug; 13(8):301-6. PubMed ID: 7544984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo RNA transcript-releasing plasmid possessing a universal pseudo-terminator by means of artificial ribozymes.
    Ohme-Takagi M; Shinshi H; Oda M; Uchimaru T; Nishikawa S; Taira K
    Nucleic Acids Symp Ser; 1990; (22):49-50. PubMed ID: 1714571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction of new hairpin ribozymes with replaced domains.
    Komatsu Y; Kanzaki I; Koizumi M; Ohtsuka E
    Nucleic Acids Symp Ser; 1995; (34):223-4. PubMed ID: 8841632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Catalytic strategies of the hepatitis delta virus ribozymes.
    Shih IH; Been MD
    Annu Rev Biochem; 2002; 71():887-917. PubMed ID: 12045114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Group I intron ribozymes.
    Nielsen H
    Methods Mol Biol; 2012; 848():73-89. PubMed ID: 22315064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hammerhead ribozymes as therapeutic agents for bladder cancer.
    Irie A; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
    Mol Urol; 2000; 4(2):61-6. PubMed ID: 12006244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection.
    Welch PJ; Tritz R; Yei S; Leavitt M; Yu M; Barber J
    Gene Ther; 1996 Nov; 3(11):994-1001. PubMed ID: 9044745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ribozymes, catalytically active RNA molecules. Introduction.
    Westhof E
    Methods Mol Biol; 2012; 848():1-4. PubMed ID: 22315059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expanding the catalytic repertoire of ribozymes and deoxyribozymes beyond RNA substrates.
    Franzen S
    Curr Opin Mol Ther; 2010 Apr; 12(2):223-32. PubMed ID: 20373266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expressing ribozymes in plants.
    de Feyter R; Gaudron J
    Methods Mol Biol; 1997; 74():403-15. PubMed ID: 9204456
    [No Abstract]   [Full Text] [Related]  

  • 38. Minimized hammerhead ribozymes.
    McCall MJ; Hendry P; Lockett TJ
    Methods Mol Biol; 1997; 74():151-9. PubMed ID: 9204430
    [No Abstract]   [Full Text] [Related]  

  • 39. [Circumventing multidrug resistance in human cancer by anti-ribozyme].
    Funato T
    Nihon Rinsho; 1997 May; 55(5):1116-21. PubMed ID: 9155162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Internal symmetry of the mirror type in the primary structure of ribozymes].
    Shpakov AO
    Tsitologiia; 2002; 44(6):561-9. PubMed ID: 12236100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.